Literature DB >> 27793648

Shikonin regulates C-MYC and GLUT1 expression through the MST1-YAP1-TEAD1 axis.

Karel Vališ1, Pavel Talacko2, Valéria Grobárová2, Jan Černý3, Petr Novák4.   

Abstract

The general mechanism underlying the tumor suppressor activity of the Hippo signaling pathway remains unclear. In this study, we explore the molecular mechanisms connecting the Hippo signaling pathway with glucose metabolism. We have found that two key regulators of glycolysis, C-MYC and GLUT1, are targets of the Hippo signaling pathway in human leukemia cells. Our results revealed that activation of MST1 by the natural compound shikonin inhibited the expression of GLUT1 and C-MYC. Furthermore, RNAi experiments confirmed the regulation of GLUT1 and C-MYC expression via the MST1-YAP1-TEAD1 axis. Surprisingly, YAP1 was found to positively regulate C-MYC mRNA levels in complex with TEAD1, while it negatively regulates C-MYC levels in cooperation with MST1. Hence, YAP1 serves as a rheostat for C-MYC, which is regulated by MST1. In addition, depletion of MST1 stimulates lactate production, whereas the specific depletion of TEAD1 has an opposite effect. The inhibition of lactate production and cellular proliferation induced by shikonin also depends on the Hippo pathway activity. Finally, a bioinformatic analysis revealed conserved TEAD-binding motifs in the C-MYC and GLUT1 promoters providing another molecular data supporting our observations. In summary, regulation of glucose metabolism could serve as a new tumor suppressor mechanism orchestrated by the Hippo signaling pathway.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C-MYC; GLUT1; Glycolysis; Hippo; TEAD1; YAP1

Mesh:

Substances:

Year:  2016        PMID: 27793648     DOI: 10.1016/j.yexcr.2016.10.018

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  9 in total

1.  TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC.

Authors:  Stacy Grieve; Gabriel Wajnberg; Miranda Lees; Simi Chacko; Jackson Weir; Nicolas Crapoulet; Tony Reiman
Journal:  Blood Adv       Date:  2019-11-26

Review 2.  YAP/TAZ-mediated activation of serine metabolism and methylation regulation is critical for LKB1-deficient breast cancer progression.

Authors:  Qi Wu; Juanjuan Li; Si Sun; Xinyue Chen; Hanpu Zhang; Bei Li; Shengrong Sun
Journal:  Biosci Rep       Date:  2017-10-24       Impact factor: 3.840

3.  Reprogramming of leukemic cell metabolism through the naphthoquinonic compound Quambalarine B.

Authors:  Karel Vališ; Valéria Grobárová; Lucie Hernychová; Martina Bugáňová; Daniel Kavan; Martin Kalous; Jiří Černý; Eva Stodůlková; Marek Kuzma; Miroslav Flieger; Jan Černý; Petr Novák
Journal:  Oncotarget       Date:  2017-10-07

Review 4.  Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.

Authors:  Maria Ferraiuolo; Lorena Verduci; Giovanni Blandino; Sabrina Strano
Journal:  Int J Mol Sci       Date:  2017-05-03       Impact factor: 5.923

Review 5.  Lactoferrin, a unique molecule with diverse therapeutical and nanotechnological applications.

Authors:  Sally Sabra; Mona M Agwa
Journal:  Int J Biol Macromol       Date:  2020-07-22       Impact factor: 6.953

6.  The MEK-ERK-MST1 Axis Potentiates the Activation of the Extrinsic Apoptotic Pathway during GDC-0941 Treatment in Jurkat T Cells.

Authors:  Jana Nováková; Pavel Talacko; Petr Novák; Karel Vališ
Journal:  Cells       Date:  2019-02-21       Impact factor: 6.600

7.  Metastatic Colorectal Cancer Rewrites Metabolic Program Through a Glut3-YAP-dependent Signaling Circuit.

Authors:  Chih-Chia Kuo; Hsiang-Hsi Ling; Ming-Chen Chiang; Chu-Hung Chung; Wen-Ying Lee; Cheng-Ying Chu; Yu-Chih Wu; Cheng-Hsun Chen; Yi-Wen Lai; I-Lin Tsai; Chia-Hsiung Cheng; Cheng-Wei Lin
Journal:  Theranostics       Date:  2019-04-13       Impact factor: 11.556

8.  Hypoxia decreases macrophage glycolysis and M1 percentage by targeting microRNA-30c and mTOR in human gastric cancer.

Authors:  Yun Zhihua; Tan Yulin; Wang Yibo; Ding Wei; Chu Yin; Xu Jiahao; Jiang Runqiu; Xu Xuezhong
Journal:  Cancer Sci       Date:  2019-07-12       Impact factor: 6.716

Review 9.  Targeting ERK-Hippo Interplay in Cancer Therapy.

Authors:  Karel Vališ; Petr Novák
Journal:  Int J Mol Sci       Date:  2020-05-03       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.